Adding eight state-of-the-art suites will boost the flexible capacity for late-stage clinical trial supplies of small-molecule medicines. Serán’s ‘Right-From-the-Start’ approach includes enhancing bioavailability by improving permeability and solubility, matrix tablet- and multiparticulate-based modified release, extensive capsule and tablet capabilities, and engineered particles for inhalation.

“Serán continues to see high demand for science-based drug product services,” commented Dan Smithey, President, CEO and Co-founder of Serán BioScience. “We are excited to announce the expansion at the site, where we can now provide mid- and large-scale manufacturing unit operations to support our clients’ journey from first-in-human studies through to pivotal trials and registration.”

The new suites within Serán’s 90,000-sq ft campus in Bend feature the latest technologies for transformative pharmaceutical dosage-form solutions. The site offers clinical manufacturing for a wide range of oral solid and inhaled dosage forms, including nano milling, micronization, particle engineering, spray-dried dispersions, twin-screw melt extrusion, tablet compression, coating, encapsulation, and clinical packaging and labeling.